Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Melanoma
Study Name
S1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Principal Investigator
Gordan Srkalovic
Study Information
https://clinicaltrials.gov/ct2/show/NCT03698019
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance